TIGERMED Launches RMB500 Million–1 Billion A-Share Buyback for Incentives and Capital Reduction

Bulletin Express
05/19

Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) plans to repurchase between RMB500 million and RMB1 billion of its A-shares through centralized price bidding, according to a circular dated 19 May 2026.

Key terms • Price cap: RMB60.00 per share, no higher than 150% of the average trading price over the 30 trading days prior to the board approval on 13 May 2026. • Estimated volume: 8.33 million–16.67 million A-shares, equivalent to 0.97%–1.94% of total issued shares and 1.13%–2.26% of A-share capital. • Use of shares: up to 60% will serve future equity incentive or employee stock-ownership plans; at least 40% will be cancelled to reduce registered capital. • Funding source: the company’s own or self-raised funds; no proceeds from the previous H-share issuance will be used. • Timeline: buyback window extends up to 12 months after shareholder approval or ends earlier if the RMB1 billion ceiling is reached or the general meeting terminates the programme. • Trading blackout: no repurchases during opening/closing call auctions, trading days without price limits, or periods involving undisclosed material events.

Financial impact As of 31 March 2026 (unaudited), TIGERMED reported total assets of RMB28.80 billion, shareholders’ equity of RMB20.92 billion and current assets of RMB6.63 billion. A full RMB1 billion buyback would account for 3.47% of total assets, 4.78% of shareholders’ equity and 15.08% of current assets. Management states the exercise will not materially affect operations, liquidity or future development.

Shareholder meetings The second extraordinary general meeting and corresponding A- and H-share class meetings will be held on 9 June 2026 in Hangzhou to vote on the special resolution authorising the buyback and related mandates.

Record date The register of H-shareholders will be closed from 4 June to 9 June 2026 inclusive; transfers must be lodged by 16:30 on 3 June 2026 to qualify for voting rights.

If approved, the board will be authorised to adjust buyback parameters, open specific securities accounts, amend the articles of association for capital changes, and handle all ancillary matters until completion of the programme.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10